These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 10813375)

  • 1. Beneficial effects of fluvastatin on myocardial blood flow at two time-points in hypercholesterolemic patients with coronary artery disease.
    Eichstädt HW; Abletshauser CB; Störk T; Weidinger G
    J Cardiovasc Pharmacol; 2000 May; 35(5):735-40. PubMed ID: 10813375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease.
    Eichstädt HW; Eskötter H; Hoffman I; Amthauer HW; Weidinger G
    Am J Cardiol; 1995 Jul; 76(2):122A-125A. PubMed ID: 7604786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed response of myocardial flow reserve to lipid-lowering therapy with fluvastatin.
    Guethlin M; Kasel AM; Coppenrath K; Ziegler S; Delius W; Schwaiger M
    Circulation; 1999 Feb; 99(4):475-81. PubMed ID: 9927392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a 3-year therapy with the 3-hydroxy-3-methylglutaryl coenzyme a reductase-inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient.
    Kosch M; Barenbrock M; Suwelack B; Schaefer RM; Rahn KH; Hausberg M
    Am J Kidney Dis; 2003 May; 41(5):1088-96. PubMed ID: 12722044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluvastatin in severe hypercholesterolemia: analysis of a clinical trial database.
    Peters TK
    Am J Cardiol; 1995 Jul; 76(2):71A-75A. PubMed ID: 7604803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between hypercholesterolemia, lipid-lowering therapy and coronary flow velocity reserve evaluated by stress transesophageal echocardiography in patients with a negative coronary angiogram.
    Nemes A; Neu K; Forster T; Gruber N; Csanády M
    Echocardiography; 2004 Jan; 21(1):37-41. PubMed ID: 14717719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine.
    Goldberg RB; Roth D
    Am J Cardiol; 1995 Jul; 76(2):107A-109A. PubMed ID: 7604782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluvastatin in primary hypercholesterolemia: efficacy and safety in patients at high risk. An analysis of a clinical trial database.
    Peters TK; Muratti EN; Mehra M
    Am J Med; 1994 Jun; 96(6A):79S-83S. PubMed ID: 8017471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia.
    West MS; Herd JA; Ballantyne CM; Pownall HJ; Simpson S; Gould L; Gotto AM
    Control Clin Trials; 1996 Dec; 17(6):550-83. PubMed ID: 8974213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin Study Group.
    Farnier M; Dejager S
    Am J Cardiol; 2000 Jan; 85(1):53-7. PubMed ID: 11078237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine.
    Holdaas H; Hartmann A; Stenstrøm J; Dahl KJ; Borge M; Pfister P
    Am J Cardiol; 1995 Jul; 76(2):102A-106A. PubMed ID: 7604781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasodilatory capacity of forearm resistance vessels is augmented in hypercholesterolemic patients after treatment with fluvastatin.
    Schobel HP; Schmieder RE
    Angiology; 1998 Sep; 49(9):743-8. PubMed ID: 9756426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in plasma apolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine. European Fluvastatin Study Group.
    Bard JM; Ose L; Hagen E; Duriez P; Pfister P; Fruchart JC; Dallongeville J
    Am J Cardiol; 1995 Jul; 76(2):65A-70A. PubMed ID: 7604802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluvastatin alters platelet aggregability in patients with hypercholesterolemia: possible improvement of intraplatelet redox imbalance via HMG-CoA reductase.
    Haramaki N; Ikeda H; Takenaka K; Katoh A; Sugano R; Yamagishi S; Matsuoka H; Imaizumi T
    Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1471-7. PubMed ID: 17379842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.
    Plosker GL; Wagstaff AJ
    Drugs; 1996 Mar; 51(3):433-59. PubMed ID: 8882381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluvastatin reduces levels of plasma apo B-containing particles and increases those of LpA-I. European Fluvastatin Study Group.
    Dallongeville J; Fruchart JC; Pfister P; Bard JM
    Am J Med; 1994 Jun; 96(6A):32S-36S. PubMed ID: 8017464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the lipid-related effects of fluvastatin.
    Liberopoulos EN; Daskalopoulou SS; Mikhailidis DP; Wierzbicki AS; Elisaf MS
    Curr Med Res Opin; 2005 Feb; 21(2):231-44. PubMed ID: 15801994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluvastatin attenuates nitrate tolerance in patients with ischemic heart disease complicating hypercholesterolemia.
    Inoue T; Takayanagi K; Hayashi T; Morooka S
    Int J Cardiol; 2003 Aug; 90(2-3):181-8. PubMed ID: 12957750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of fluvastatin on lipid profile and apolipoproteins in Chinese patients with hypercholesterolemia.
    Tomlinson B; Mak TW; Tsui JY; Woo J; Shek CC; Critchley JA; Masarei JR
    Am J Cardiol; 1995 Jul; 76(2):136A-139A. PubMed ID: 7604789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid-lowering therapy with fluvastatin inhibits oxidative modification of low density lipoprotein and improves vascular endothelial function in hypercholesterolemic patients.
    Inoue T; Hayashi M; Takayanagi K; Morooka S
    Atherosclerosis; 2002 Feb; 160(2):369-76. PubMed ID: 11849660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.